Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT05074927
Active, not recruiting Not applicable

Pulmonary Function in Patients Recovering From COVID19 Infection : a Pilot Study

NCT05074927 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Limoges
Phase
Not applicable
Started
2022-01-31
Last updated
2026-06-26

Condition(s) studied

COVID-19

Investigational drug(s) / intervention(s)

diaphragm ultrasonography

diaphragm ultrasonography: For all patients with confirmed COVID-19 who had been discharged from CHRU Hospital in Limoges (France) : diaphragm ultrasonography at 3 (M0) and 6 months (M3) after the end of his hospitalisation

Study summary

The current state of knowledge shows the presence of respiratory sequelae after acute infection with COVID-19 and the importance of these long-term respiratory dysfunctions have to be determined.

Aim of our study is describe diaphragmatic amplitude using diaphragm ultrasonography in patients recovering from SARS-CoV-2 pneumonia at 3 and 6 months after the acute episode.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * SARS-CoV-2 infection proven by RT-PCR. * Patient hospitalised for the management of SARS-CoV-2 infection and included 3 months after the end of his hospitalisation at the CHU of Limoges. * Patient of legal age. * Patient affiliated to a social security regime. * Patient having given informed consent Exclusion Criteria: * Known pregnancy. * Patients who are contraindicated to perform the 6-minute walk test. * Patients unable to understand or adhere to the protocol. * Patients deprived of liberty. * Patients under court order, tutorship or curatorship. * Minor patients

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
CHU Dupuytren Limoges France
chu Limoges Limoges France

More University Hospital, Limoges trials in France

Clinical Relevance of Detecting Molecular Abnormalities in Glial Tumor Exosomes Recruiting
Hemodynamic Impact of the Spontaneous Ventilation Test in Patients at Risk of Weaning Pulmonary Oedema Starting soon
French Colorectal ESD Cohort in Experts Centers Recruiting
Long Term Follow up of a Cohort of Children With TCF2 Mutation:Evolution of Endocrine and Renal Function Active, not recruiting
Identification and Characterisation of IgA With Nephritogenic Potential in IgA Deposition Nephropathies (Rep-IgAN) Recruiting

Other trials for the same condition

Treatment of COVID-19 by Nebulization of Inteferon Beta 1b Efficiency and Safety Study Active, not recruiting
Understanding the Determinants of Mucosal Immunity and Optimizing the Diagnosis of Infection With SARS-CoV-2 Variants Recruiting
Evaluation of Concordance Between Exhaled Air Test (eBAM-CoV) and RT-PCR to Detect SARS-CoV-2 Recruiting
Prevalence and Clinical Significance of Anti-annexin A2 Antibodies in COVID-19 Infection Recruiting
Effect of a Health Pathway for People With Persistent Symptoms Covid-19 Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05074927 on ClinicalTrials.gov ↗ ← All trials in France